Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Anand Ashwin Patel, MD, Joseph Heng, MD, Emily Dworkin, PharmD, Sarah Monick, MD, Benjamin A Derman, MD, Sandeep Gurbuxani, MBBS, PhD, Satyajit Kosuri, MD, Hongtao Liu, MD PhD, Michael Thirman, MD, Lucy A. Godley, Olatoyosi Odenike, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138967

Published: 2020

Journal Articles

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Hongtao Liu, MD PhD, Bulent Aydogan, MD, Yasmin Hasan, MD, Amy Wang, MD MPH, Kamil Yenice, MD, Julien Partouche, MD, Wendy Stock, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, James LaBelle, MD PhD, Justin Kline, MD, Peter A. Riedell, MD, Andrew S. Artz, MD, Michael R. Bishop, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138554

Published: 2020

Journal Articles

Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, MD, Gail J. Roboz, MD, Marina Konopleva, MD PhD, Hongtao Liu, MD PhD, Elias Jabbour, MD, Camille Poirot, Pharm.D., Cécile Schiffer-Manniou, PhD, Agnès Gouble, PhD, Asifa Haider, PhD, Oleg Zernovak, MD, Richard A. Larson, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138594

Published: 2020

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Kirk Cahill, MD, Anand Ashwin Patel, MD, Hongtao Liu, MD PhD, Sandeep Gurbuxani, MBBS, PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Wendy Stock, MD, Jeremy Segal, MD PhD, Olatoyosi Odenike, MD

Blood (2019) 134 (Supplement_1): 4176.

https://doi.org/10.1182/blood-2019-122380

Published: 2019

Journal Articles

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Satyajit Kosuri, MD, Sang Mee Lee, PhD, Hongtao Liu, MD PhD, Mylove Mortel, MS, RN, Lucy A Godley, MD PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Wendy Stock, MD, Justin Kline, MD, Peter A. Riedell, MD, Koen Van Besien, MD PhD, Michael R. Bishop, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 3324.

https://doi.org/10.1182/blood-2019-126211

Published: 2019

Journal Articles

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Amy Wang, MD MPH, Howard Weiner, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew S Artz, MD, Michael R. Bishop, MD, Lucy Godley, MD PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Jane Churpek, MD, Emily K Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MD PhD

Blood (2018) 132 (Supplement 1): 4073.

https://doi.org/10.1182/blood-2018-99-120244

Published: 2018

Journal Articles

Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation

Justin Kline, MD, Hongtao Liu, MD PhD, Tallarico Michael, MD, Andrew S Artz, MD, James Godfrey, MD, Emily K Curran, MD, Wendy Stock, MD, Sonali M. Smith, MD, Michael R. Bishop, MD

Blood (2018) 132 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2018-99-115108

Published: 2018

Journal Articles

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Kothari Shawn, MD, Andrew Artz, MD, Sang Mee Lee, PhD, Noreen Fulton, BS, Jae-Hyun Park, Wendy Stock, MD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Justin Kline, MD, Lucy Godley, MD PhD, James LaBelle, MD PhD, Satyajit Kosuri, MD, Peter A Riedell, MD, Yusuke Nakamura, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2017) 130 (Supplement 1): 4572.

https://doi.org/10.1182/blood.V130.Suppl_1.4572.4572

Published: 2017

Journal Articles

Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT)

Michael J. Leukam, MD, Lucy Godley, MD PhD, Justin Kline, MD, Richard A. Larson, MD, Hongtao Liu, MD PhD, Olatoyosi Odenike, MD, Wendy Stock, MD, Michael R. Bishop, MD, Andrew Artz, MD

Blood (2017) 130 (Supplement 1): 4558.

https://doi.org/10.1182/blood.V130.Suppl_1.4558.4558

Published: 2017

Journal Articles

Fludarabine Melphalan Conditioning Followed By T-Replete Haplo Identical (Haplo) Transplantation or Haplo Cord (HC) Transplantation

Koen Van Besien, MD PhD, Andrew Artz, MD, Richard E Champlin, MD, Danielle Guarneri, Michael R. Bishop, MD, Julianne Chen, Tsiporah B. Shore, MD, Hongtao Liu, MD PhD, Gabriela Rondon, MD, Sebastian A. Mayer, MD, Stefan O. Ciurea

Blood (2017) 130 (Supplement 1): 3328.

https://doi.org/10.1182/blood.V130.Suppl_1.3328.3328

Published: 2017

Journal Articles

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Hongtao Liu, MD PhD, Andrew Artz, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, Wendy Stock, MD, Michael R. Bishop, MD

Blood (2017) 130 (Supplement 1): 3312.

https://doi.org/10.1182/blood.V130.Suppl_1.3312.3312

Published: 2017

Journal Articles

TCR Clonal Evolution in AML Patients in Morphologic Remission Treated with Anti-PD1 Antibody, Nivolumab

Hongtao Liu, MD PhD, Jae-Hyun Park, PhD, Noreen Fulton, Kazuma Kiyotani, PhD, Yusuke Nakamura, MD, Olatoyosi Odenike, MD, Wendy Stock, MD

Blood (2016) 128 (22): 2325.

https://doi.org/10.1182/blood.V128.22.2325.2325

Published: 2016

Journal Articles

Identification of Specific Hnrnps As Novel Therapeutic Targets and Responsive Indicators of KPT330 (selinexor) in Leukemia

Adam Cloe, MD PhD, Li Chen, MD PhD, Yuan Li, MD, Hongtao Liu, MD PhD, Jason X. Cheng, MD PhD

Blood (2016) 128 (22): 1657.

https://doi.org/10.1182/blood.V128.22.1657.1657

Published: 2016

Journal Articles

Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality

Christopher Robert D'Angelo, MD, Brianna Novitsky, BA, Sang Mee Lee, PhD, Lucy A Godley, MD PhD, Justin Kline, MD, Richard A. Larson, MD, Hongtao Liu, MD PhD, Olatoyosi Odenike, MD, Wendy Stock, MD, Michael R. Bishop, MD, Andrew Artz, MD

Blood (2016) 128 (22): 5844.

https://doi.org/10.1182/blood.V128.22.5844.5844

Published: 2016

Journal Articles

WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia

Hongtao Liu, MD PhD, Yuanyuan Zha, PhD, Gregory Malnassy, Noreen Fulton, Margaret Green, Jae-Hyun Park, PhD, Yusuke Nakamura, MD, Richard A. Larson, MD, Andres M Salazar, Olatoyosi Odenike, MD, Thomas Gajewski, MD PhD, Wendy Stock, MD

Blood (2016) 128 (22): 3984.

https://doi.org/10.1182/blood.V128.22.3984.3984

Published: 2016

Journal Articles

The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago

Yun Fan, MD, Andrew S. Artz, MD MS, Koen van Besien, MD, Wendy Stock, MD, Richard A. Larson, Olatoyosi Odenike, MD, Lucy A Godley, MD PhD, Justin Kline, MD, John M Cunningham, MD, James LaBelle, MD PhD, Michael R Bishop, MD, Hongtao Liu, MD PhD

Blood (2014) 124 (21): 2509.

https://doi.org/10.1182/blood.V124.21.2509.2509

Published: 2014

Journal Articles

Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation

Stephanie B. Tsai, MD MA, Hongtao Liu, MD PhD, Tsiporah B. Shore, MD, Michael R Bishop, MD, Melissa M. Cushing, MD, Yun Fan, MD, Usama Gergis, MD, Lucy A Godley, MD PhD, Justin Kline, MD, Richard A. Larson, Guadalupe G. Martinez, BS, Sebastian Mayer, MD, Olatoyosi Odenike, MD, Wendy Stock, MD, Amittha Wickrema, PhD, Koen van Besien, MD PhD, Andrew S. Artz, MD MS

Blood (2014) 124 (21): 2463.

https://doi.org/10.1182/blood.V124.21.2463.2463

Published: 2014

Journal Articles

Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA)

Christopher R D'Angelo, MD, Masha Kocherginsky, PhD, Michael R Bishop, MD, Lucy A Godley, MD PhD, Justin Kline, MD, Richard A. Larson, Hongtao Liu, MD PhD, Olatoyosi Odenike, MD, Jennifer Pisano, MD, Wendy Stock, MD, Andrew Artz, MD MS

Blood (2014) 124 (21): 2464.

https://doi.org/10.1182/blood.V124.21.2464.2464

Published: 2014

Journal Articles

Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study

Koen van Besien, MD PhD, Hongtao Liu, MD PhD, Usama Gergis, MD, Melissa M. Cushing, MD, Stephanie Tsai, MD, Sebastian Mayer, MD, Amittha Wickrema, PhD, Wendy Stock, MD, Richard A. Larson, Tsiporah B. Shore, MD, Olatoyosi Odenike, MD, Roger N Pearse, MD PhD, Lucy A Godley, MD PhD, Tomer M Mark, MD MSc, Justin Kline, MD, John M Cunningham, MD, James LaBelle, MD PhD, Michael R Bishop, MD, Andrew S. Artz, MD MS

Blood (2014) 124 (21): 1093.

https://doi.org/10.1182/blood.V124.21.1093.1093

Published: 2014

NARROW

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT)

Fludarabine Melphalan Conditioning Followed By T-Replete Haplo Identical (Haplo) Transplantation or Haplo Cord (HC) Transplantation

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

TCR Clonal Evolution in AML Patients in Morphologic Remission Treated with Anti-PD1 Antibody, Nivolumab

Identification of Specific Hnrnps As Novel Therapeutic Targets and Responsive Indicators of KPT330 (selinexor) in Leukemia

Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality

WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia

The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago

Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation

Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA)

Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only